DR-340 Discovering novel noncoding cancer drivers using genomic conformation and context models

No Featured Image set

Cancer cells are characterized by the accumulation of genetic mutations, only few of which are needed to trigger the malignancy. Previous research has focused on coding mutations, which directly alter the genetic function, and has been successful in revealing recurring cancer-promoting mechanisms. However, the majority of the mutations are harbored in the noncoding genome, which remains largely uncharted, and would benefit patients lacking known coding mutations. We propose to leverage this unexploited part of the genome to systematically identify cancer promoting mutations. The findings can elucidating novel cancer driving mechanisms and facilitate anticancer drug development and early diagnostics.

Felix Dietlein, Chidren’s Hospital Boston, USA

Terug naar nieuws

Meer nieuws

Therapie-succes voorspellen op basis van genexpressie 

Therapie-succes voorspellen op basis van genexpressie 

17-12-2024

Naast Whole Genome Sequencing van DNA, doet Hartwig Medical Foundation Whole Transcriptome Sequencing van RNA. Onderzoekster Marjolein Lansbergen maakte hier …

GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’

GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’

10-11-2016

The project is an attempt to address the rising healthcare costs associated with new cancer drugs and to identify biomarkers …

Een Vandaag: Databank kanker kan levens gaan redden

Een Vandaag: Databank kanker kan levens gaan redden

30-01-2017

Vier jaar geleden moest Commissaris van de Koning in Gelderland, Clemens Cornielje, afscheid nemen van het leven. Hij had uitgezaaide …

Wilt u op de hoogte blijven van nieuwe ontwikkelingen?

Abonneer u op onze nieuwsbrieven

Meer weten over de complete DNA-test?

Ga naar OncoAct.nl